Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM313 vs Pioglitazone in Obese Participants
NCT03298464Phase 1Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Sep 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NGM313 in obesity, non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) (2 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Evaluation of whole body insulin sensitivity measured as insulin sensitivity index (M and Si) following intravenous insulin administration at 28 Days. Started Sep 2017; status: completed.
02
Drugs
NGM313
03
Conditions
obesitynon-alcoholic fatty liver disease (NAFLD)insulin resistance (IR)
Beyond the preview
Go deeper on NCT03298464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298464.